Apyx Medical Reports Strong Q1 Revenue Growth, Significantly Narrows Losses, and Raises Full-Year Guidance

summarizeSummary

Apyx Medical reported robust Q1 2026 financial results, including a 32.4% revenue increase and a significant reduction in net and Adjusted EBITDA losses, leading to an upward revision of its full-year 2026 revenue guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Total revenue for the first quarter of 2026 increased 32.4% to $12.5 million, up from $9.4 million in the prior year period, primarily driven by 36% growth in the Surgical Aesthetics segment.

• Significantly Narrowed Losses

  Net loss attributable to stockholders improved to $2.1 million, compared to a $4.2 million loss in Q1 2025. Adjusted EBITDA loss also significantly narrowed to $0.3 million from $2.4 million in the prior year.

• Raised Full-Year 2026 Revenue Guidance

  The company increased its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, up from the previous guidance of $57.5 million to $58.5 million.

• Solid Cash Position

  Apyx Medical reported cash and cash equivalents of $31.1 million as of March 31, 2026, with management projecting sufficient cash through 2027.

auto_awesomeAnalysis

Apyx Medical's first-quarter results demonstrate strong operational execution, with substantial revenue growth driven by its Surgical Aesthetics segment and the AYON Body Contouring System. The significant reduction in net loss and Adjusted EBITDA loss indicates improved financial health and efficiency. The decision to raise full-year revenue guidance signals management's increased confidence in continued growth and profitability, which is a strong positive indicator for investors. The company's cash position also provides a solid runway for operations through 2027.